secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001193125-23-276225
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney reports positive Phase 2 data for REACT; narrows Phase 3 enrollment; appoints new CEO
--------------------------------------------------------------------------------

- Positive interim Phase 2 data: REACT preserved kidney function up to 30 months in high-risk Stage 3b/4 diabetic CKD patients.
- Phase 3 proact 1 protocol modified: eGFR range narrowed to 20-35 ml/min/1.73m2; enrollment paused until H1 2024.
- Manufacturing paused due to QP audit documentation deficiencies; no safety issues; expected to resume H1 2024.
- Bruce Culleton appointed CEO effective Nov 15, 2023; Tim Bertram transitions to scientific advisory role.
- Cash and marketable securities $396M as of Sept 30, 2023; funding into Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/0001193125-23-276225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000119312523276225/d83356d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-276225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer